Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract.
Pertussis toxin (PT), a secreted virulence factor of Bordetella pertussis, ADP ribosylates mammalian G(i) proteins and plays an important early role in respiratory tract infection by this pathogen in a mouse intranasal infection model. To test the hypothesis that PT targets resident airway macrophages (AM) to promote this infection, we depleted AM by intranasal administration of liposome-encapsulated clodronate prior to bacterial inoculation. This treatment enhanced respiratory tract infection by B. pertussis, even though it also induced a rapid influx of neutrophils to the airways. Strikingly, AM depletion also enhanced infection by mutant strains deficient in PT production or activity to the same level as the wild-type infection, indicating that AM may be the primary target cells for PT in promoting infection. The enhancing effect of clodronate-liposome treatment on infection (i) was shown to be due to macrophage depletion rather than neutrophil influx; (ii) was observed for both tracheal infection and lung infection; (iii) was observed during the early and peak phases of the infection but was lost by day 14 postinoculation, during clearance of the infection; (iv) persisted for at least 1 week (prior to bacterial inoculation); and (v) was equivalent in magnitude to the effect of PT pretreatment and the effects were not additive, consistent with the idea that PT targets AM. We found that PT efficiently ADP ribosylated AM G proteins both in vitro and after intranasal administration of PT in mice and that the duration of G protein modification in vivo was equivalent to the duration of the enhancing effect of PT treatment on the bacterial infection. Collectively, these observations indicate that PT targets AM to promote early infection of the respiratory tract by B. pertussis.
Carbonetti
Nicholas H
NH
Department of Microbiology and Immunology, University of Maryland School of Medicine, 660 W. Redwood St., HH 324, Baltimore, MD 21201, USA. ncarbone@umaryland.edu
Artamonova
Galina V
GV
Van Rooijen
Nico
N
Ayala
Victor I
VI
D000246:Adenosine Diphosphate Ribose; D000818:Animals; D001886:Bordetella pertussis / Q000502:physiology*; D004002:Clodronic Acid / Q000008:administration & dosage / Q000494:pharmacology; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D005260:Female; D019204:GTP-Binding Proteins / Q000378:metabolism; D007155:Immunologic Factors / Q000008:administration & dosage / Q000494:pharmacology; D047589:Leukocyte Reduction Procedures; D008168:Lung / Q000382:microbiology; D008264:Macrophages / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils / Q000276:immunology; D037342:Pertussis Toxin / Q000235:genetics / Q000378:metabolism* / Q000633:toxicity*; D012137:Respiratory System / Q000276:immunology* / Q000382:microbiology* / Q000473:pathology; D014132:Trachea / Q000382:microbiology; D014917:Whooping Cough / Q000276:immunology* / Q000382:microbiology
D007155:Immunologic Factors; D004002:Clodronic Acid; D000246:Adenosine Diphosphate Ribose; D037342:Pertussis Toxin; D019204:GTP-Binding Proteins